FDA official denies politics delaying Plan B decision

Share this article:
The FDA’s acting director refuted concerns that politics are delaying the agency’s review of an OTC switch petition for Plan B, the AP reports. Andrew von Eschenbach told House members that the decision on the morning-after contraceptive pill, marketed by Barr Labs, would be based on science. "That process will be carried out in the appropriate fashion," he said, while appearing before a House Appropriations subcommittee to go over the agency's budget. House Democrats pressed von Eschenbach on the issue, saying the agency has had ample time to reach a decision. Under Barr’s revised application—the FDA rejected its initial OTC petition in 2004—Plan B would become available over the counter to patients 16 and above but remain a prescription drug for younger ones. Those age limits create a novel situation for the FDA, which has not considered the same product as both a prescription and OTC drug. Von Eschenbach declined to say when the agency might rule, adding that it was reviewing public comment.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.